Please enter your username below and press the send button.A password reset link will be sent to you.
If you are unable to access the email address originally associated with your Delicious account, we recommend creating a new account.
Following: 0 Users
Headline: Hopelessly peripatetic. Thoughts and actions ranging from post-Pasteurian microbiology, indiscriminate writing and post-digital media, various forms of performances thespian and corporate, the Long Now and a post-electronic age, and transforming natural philosophy in the 21st century.
This link recently saved by cschick on July 06, 2011
"Some members of the advisory committee pointed to a downside in today's decision to strip the drug of its breast cancer label: This could undermine the accelerated approval process under which Avastin first got FDA's blessing. Accelerated approval is a way to get drugs to the sickest patients more quickly, with less clinical data. It's virtually unheard of for FDA to reverse such an approval. In this case, FDA did so, agency officials said, after subsequent studies showed that the benefit was much less than initially thought."
I've been following pharmacoepidemiology quite a lot lately, mostly because one of the product we sell (and I market) is used to look the effectiveness of drugs, help understand if there might be some off-label uses, and help drugs like Avastin succeed in their selected market and others that might also work. Of course, I'm now going to see how this deregulation can be avoided with better data analysis.
This link recently saved by cschick on February 20, 2011
"I've pulled out from Baum's comments a range of timely ideas that help bring some perspective to the rapidly evolving and often-intersecting areas of data warehousing, purpose-built appliances, business analytics, Big Data, and how companies are trying to leverage all of that to turn insight into foresight."